|
1
|
Haruyama Y and Kataoka H: Glypican-3 is a
prognostic factor and an immunotherapeutic target in hepatocellular
carcinoma. World J Gastroenterol. 22:275–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fransson LA: Glypicans. Int J Biochem Cell
Biol. 35:125–129. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Filmus J, Shi W, Wong ZM and Wong MJ:
Identification of a new membrane-bound heparan sulphate
proteoglycan. Biochem J. 311:561–565. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Cat B, Muyldermans SY, Coomans C,
Degeest G, Vanderschueren B, Creemers J, Biemar F, Peers B and
David G: Processing by proprotein convertases is required for
glypican-3 modulation of cell survival, Wnt signaling, and
gastrulation movements. J Cell Biol. 163:625–635. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iglesias BV, Centeno G, Pascuccelli H,
Ward F, Peters MG, Filmus J, Puricelli L and de Kier Joffé EB:
Expression pattern of glypican-3 (GPC3) during human embryonic and
fetal development. Histol Histopathol. 23:1333–1340.
2008.PubMed/NCBI
|
|
6
|
Hsu HC, Cheng W and Lai PL: Cloning and
expression of a developmentally regulated transcript MXR7 in
hepatocellular carcinoma: Biological significance and
temporospatial distribution. Cancer Res. 57:5179–5184.
1997.PubMed/NCBI
|
|
7
|
Ho M and Kim H: Glypican-3: A new target
for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li J, Gao JZ, Du JL and Wei LX: Prognostic
and clinicopathological significance of glypican-3 overexpression
in hepatocellular carcinoma: A meta-analysis. World J
Gastroenterol. 20:6336–6344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu JW, Zuo XL and Wang S: Diagnosis
accuracy of serum Glypican-3 level in patients with hepatocellular
carcinoma and liver cirrhosis: A meta-analysis. Eur Rev Med
Pharmacol Sci. 19:3655–3673. 2015.PubMed/NCBI
|
|
10
|
Capurro MI, Xiang YY, Lobe C and Filmus J:
Glypican-3 promotes the growth of hepatocellular carcinoma by
stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kolluri A and Ho M: The role of glypican-3
in regulating Wnt, Yap, and Hedgehog in liver cancer. Front Oncol.
9:7082019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Filmus J and Capurro M: The role of
glypican-3 in the regulation of body size and cancer. Cell Cycle.
7:2787–2790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saikali Z and Sinnett D: Expression of
glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 89:418–422.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ota S, Hishinuma M, Yamauchi N, Goto A,
Morikawa T, Fujimura T, Kitamura T, Kodama T, Aburatani H and
Fukayama M: Oncofetal protein glypican-3 in testicular germ-cell
tumor. Virchows Arch. 449:308–314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamanaka K, Ito Y, Okuyama N, Noda K,
Matsumoto H, Yoshida H, Miyauchi A, Capurro M, Filmus J and Miyoshi
E: Immunohistochemical study of glypican 3 in thyroid cancer.
Oncology. 73:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baumhoer D, Tornillo L, Stadlmann S,
Roncalli M, Diamantis EK and Terracciano LM: Glypican 3 expression
in human nonneoplastic, preneoplastic, and neoplastic tissues: A
tissue microarray analysis of 4,387 tissue samples. Am J Clin
Pathol. 129:899–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zynger DL, Everton MJ, Dimov ND, Chou PM
and Yang XJ: Expression of glypican 3 in ovarian and extragonadal
germ cell tumors. Am J Clin Pathol. 130:224–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao D, Li J, Guo CC, Allan RW and Humphrey
PA: SALL4 is a novel diagnostic marker for testicular germ cell
tumors. Am J Surg Pathol. 33:1065–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Liu A, Peng Y, Rakheja D, Wei L,
Xue D, Allan RW, Molberg KH, Li J and Cao D: Diagnostic utility of
SALL4 in extragonadal yolk sac tumors: An immunohistochemical study
of 59 cases with comparison to placental-like alkaline phosphatase,
alpha-fetoprotein, and glypican-3. Am J Surg Pathol. 33:1529–1539.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikeda H, Sato Y, Yoneda N, Harada K,
Sasaki M, Kitamura S, Sudo Y, Ooi A and Nakanuma Y:
α-Fetoprotein-producing gastric carcinoma and combined
hepatocellular and cholangiocarcinoma show similar morphology but
different histogenesis with respect to SALL4 expression. Hum
Pathol. 43:1955–1963. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aydin O, Yildiz L, Baris S, Dundar C and
Karagoz F: Expression of Glypican 3 in low and high grade
urothelial carcinomas. Diagn Pathol. 10:342015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nguyen T, Phillips D, Jain D, Torbenson M,
Wu TT, Yeh MM and Kakar S: Comparison of 5 immunohistochemical
markers of hepatocellular differentiation for the diagnosis of
hepatocellular carcinoma. Arch Pathol Lab Med. 139:1028–1034. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Foda AA, Mohammad MA, Abdel-Aziz A and
El-Hawary AK: Relation of glypican-3 and E-cadherin expressions to
clinicopathological features and prognosis of mucinous and
non-mucinous colorectal adenocarcinoma. Tumour Biol. 36:4671–4679.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu X, Li Y, Chen SW, Shi Y and Xu F:
Differential expression of glypican-3 (GPC3) in lung squamous cell
carcinoma and lung adenocarcinoma and its clinical significance.
Genet Mol Res. 14:10185–10192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ortiz MV, Roberts SS, Glade Bender J,
Shukla N and Wexler LH: Immunotherapeutic targeting of GPC3 in
pediatric solid embryonal tumors. Front Oncol. 9:1082019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murthy SS, Shen T, De Rienzo A, Lee WC,
Ferriola PC, Jhanwar SC, Mossman BT, Filmus J and Testa JR:
Expression of GPC3, an X-linked recessive overgrowth gene, is
silenced in malignant mesothelioma. Oncogene. 19:410–416. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiang YY, Ladeda V and Filmus J:
Glypican-3 expression is silenced in human breast cancer. Oncogene.
20:7408–7412. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peters MG, Farías E, Colombo L, Filmus J,
Puricelli L and Bal de Kier Joffé E: Inhibition of invasion and
metastasis by glypican-3 in a syngeneic breast cancer model. Breast
Cancer Res Treat. 80:221–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Valsechi MC, Oliveira AB, Conceição AL,
Stuqui B, Candido NM, Provazzi PJ, de Araújo LF, Silva WA Jr,
Calmon MF and Rahal P: GPC3 reduces cell proliferation in renal
carcinoma cell lines. BMC Cancer. 14:6312014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim H, Xu GL, Borczuk AC, Busch S, Filmus
J, Capurro M, Brody JS, Lange J, D'Armiento JM, Rothman PB, et al:
The heparan sulfate proteoglycan GPC3 is a potential lung tumor
suppressor. Am J Respir Cell Mol Biol. 29:694–701. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aviel-Ronen S, Lau SK, Pintilie M, Lau D,
Liu N, Tsao MS and Jothy S: Glypican-3 is overexpressed in lung
squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol.
21:817–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin Q, Xiong LW, Pan XF, Gen JF, Bao GL,
Sha HF, Feng JX, Ji CY and Chen M: Expression of GPC3 protein and
its significance in lung squamous cell carcinoma. Med Oncol.
29:663–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li K, Pan X, Bi Y, Xu W, Chen C, Gao H,
Shi B, Jiang H, Yang S, Jiang L, et al: Adoptive immunotherapy
using T lymphocytes redirected to glypican-3 for the treatment of
lung squamous cell carcinoma. Oncotarget. 7:2496–2507. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang Z, Jiang X, Chen S, Lai Y, Wei X, Li
B, Lin S, Wang S, Wu Q, Liang Q, et al: Anti-GPC3-CAR T Cells
Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of
Hepatocellular Carcinoma. Front Immunol. 7:6902017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakano K, Ishiguro T, Konishi H, Tanaka M,
Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K, et al:
Generation of a humanized anti-glypican 3 antibody by CDR grafting
and stability optimization. Anticancer Drugs. 21:907–916. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brinkmann U: Recombinant immunotoxins:
Protein engineering for cancer therapy. Mol Med Today. 2:439–446.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pastan I, Hassan R, Fitzgerald DJ and
Kreitman RJ: Immunotoxin therapy of cancer. Nat Rev Cancer.
6:559–565. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shapira A and Benhar I: Toxin-based
therapeutic approaches. Toxins (Basel). 2:2519–2583. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao W, Tang Z, Zhang YF, Feng M, Qian M,
Dimitrov DS and Ho M: Immunotoxin targeting glypican-3 regresses
liver cancer via dual inhibition of Wnt signalling and protein
synthesis. Nat Commun. 6:65362015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang C, Gao W, Feng M, Pastan I and Ho M:
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for
liver cancer therapy. Oncotarget. 8:32450–32460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Klijn C, Durinck S, Stawiski EW, Haverty
PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, et al: A
comprehensive transcriptional portrait of human cancer cell lines.
Nat Biotechnol. 33:306–312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weldon JE and Pastan I: A guide to taming
a toxin--recombinant immunotoxins constructed from Pseudomonas
exotoxin A for the treatment of cancer. FEBS J. 278:4683–4700.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Borowiec M, Gorzkiewicz M, Grzesik J,
Walczak-Drzewiecka A, Salkowska A, Rodakowska E, Steczkiewicz K,
Rychlewski L, Dastych J and Ginalski K: Towards Engineering Novel
PE-Based Immunotoxins by Targeting Them to the Nucleus. Toxins
(Basel). 8:3212016. View Article : Google Scholar
|
|
44
|
Repetto G, del Peso A and Zurita JL:
Neutral red uptake assay for the estimation of cell
viability/cytotoxicity. Nat Protoc. 3:1125–1131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pan F, Shen F, Yang L, Zhang L, Guo W and
Tian J: Inhibitory effects of XAV939 on the proliferation of
small-cell lung cancer H446 cells and Wnt/β-catenin signaling
pathway in vitro. Oncol Lett. 16:1953–1958. 2018.PubMed/NCBI
|
|
46
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:research0034.1. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun Ck, Chua Ms, Wei W and So S:
Glypican-3-Mediates Autophagy and Promotes Self-Renewal and Tumor
Initiation of Hepatocellular Carcinoma Cells. Biol J Stem Cell Res
Ther. 4:92014.
|
|
48
|
Ishiguro T, Sugimoto M, Kinoshita Y,
Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H,
Hamakubo T, et al: Anti-glypican 3 antibody as a potential
antitumor agent for human liver cancer. Cancer Res. 68:9832–9838.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yen CJ, Daniele B, Kudo M, Merle P, Park
JW, Ross P, Péron JO, Ebert O, Chan S, Poon RT, et al: Randomized
phase II trial of intravenous RO5137382/GC33 at 1600 mg every other
week and placebo in previously treated patients with unresectable
advanced hepatocellular carcinoma. J Clin Oncol. 32 (Suppl
5):4102a2014. View Article : Google Scholar
|
|
50
|
Feng M, Gao W, Wang R, Chen W, Man YG,
Figg WD, Wang XW, Dimitrov DS and Ho M: Therapeutically targeting
glypican-3 via a conformation-specific single-domain antibody in
hepatocellular carcinoma. Proc Natl Acad Sci USA. 110:E1083–E1091.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
FitzGerald DJ, Wayne AS, Kreitman RJ and
Pastan I: Treatment of hematologic malignancies with immunotoxins
and antibody-drug conjugates. Cancer Res. 71:6300–6309. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schulze AB, Evers G, Kerkhoff A, Mohr M,
Schliemann C, Berdel WE and Schmidt LH: Future Options of
Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers
(Basel). 11:6902019. View Article : Google Scholar
|
|
53
|
Watkins DN, Berman DM, Burkholder SG, Wang
B, Beachy PA and Baylin SB: Hedgehog signalling within airway
epithelial progenitors and in small-cell lung cancer. Nature.
422:313–317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Park KS, Martelotto LG, Peifer M, Sosml,
Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J,
et al: A crucial requirement for Hedgehog signaling in small cell
lung cancer. Nat Med. 17:1504–1508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Szczepny A, Rogers S, Jayasekara WSN, Park
K, McCloy RA, Cochrane CR, Ganju V, Cooper WA, Sage J, Peacock CD,
et al: The role of canonical and non-canonical Hedgehog signaling
in tumor progression in a mouse model of small cell lung cancer.
Oncogene. 36:5544–5550. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wagner AH, Devarakonda S, Skidmore ZL,
Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies
NC, et al: Recurrent WNT pathway alterations are frequent in
relapsed small cell lung cancer. Nat Commun. 9:37872018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Borromeo MD, Savage TK, Kollipara RK, He
M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH,
et al: ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary
Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell
Rep. 16:1259–1272. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Poirier JT, Gardner EE, Connis N, Moreira
AL, de Stanchina E, Hann CL and Rudin CM: DNA methylation in small
cell lung cancer defines distinct disease subtypes and correlates
with high expression of EZH2. Oncogene. 34:5869–5878. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Esteller L, Hernández S, Lopez-Rios F and
Remon J: Could WNT inhibitors really knock on the treatment door of
small cell lung cancer? J Thorac Dis. 11 (Suppl 3):S381–S384. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Carney DN, Gazdar AF, Bepler G, Guccion
JG, Marangos PJ, Moody TW, Zweig MH and Minna JD: Establishment and
identification of small cell lung cancer cell lines having classic
and variant features. Cancer Res. 45:2913–2923. 1985.PubMed/NCBI
|
|
61
|
Carney DN, Gazdar AF, Nau M and Minna JD:
Biological heterogeneity of small cell lung cancer. Semin Oncol.
12:289–303. 1985.PubMed/NCBI
|
|
62
|
Gazdar AF, Carney DN, Nau MM and Minna JD:
Characterization of variant subclasses of cell lines derived from
small cell lung cancer having distinctive biochemical,
morphological, and growth properties. Cancer Res. 45:2924–2930.
1985.PubMed/NCBI
|
|
63
|
Zhang Z, Zhou Y, Qian H, Shao G, Lu X,
Chen Q, Sun X, Chen D, Yin R, Zhu H, et al: Stemness and inducing
differentiation of small cell lung cancer NCI-H446 cells. Cell
Death Dis. 4:e6332013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang W, Girard L, Zhang YA, Haruki T,
Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna
JD, et al: Small cell lung cancer tumors and preclinical models
display heterogeneity of neuroendocrine phenotypes. Transl Lung
Cancer Res. 7:32–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Carney DN, Mitchell JB and Kinsella TJ: In
vitro radiation and chemotherapy sensitivity of established cell
lines of human small cell lung cancer and its large cell
morphological variants. Cancer Res. 43:2806–2811. 1983.PubMed/NCBI
|
|
66
|
Wang D, Gao Y, Zhang Y, Wang L and Chen G:
Glypican-3 promotes cell proliferation and tumorigenesis through
up-regulation of β-catenin expression in lung squamous cell
carcinoma. Biosci Rep. 39:BSR201811472019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gao W and Ho M: The role of glypican-3 in
regulating Wnt in hepatocellular carcinomas. Cancer Rep. 1:14–19.
2011.PubMed/NCBI
|
